Therapeutic compounds for immunomodulation

A peptide derivative of formula (I),

• wherein, Am1 represents 1 to 4 amino acid residues which may be same or different and each independently selected from Ser, Asn and Thr;
• wherein one of the peptide bond (—CONH—) between any two amino acid residues may be replaced with a modified peptide bond of
• wherein Q is hydrogen, —CO(C1-C20)alkyl or —COO(C1-C20)alkyl;
• Am2 is comprising of dipeptide selected from Ser-Phe or Phe-Ser, wherein Phe may be optionally substituted with amino(C1-C20)alkyl, —NHCOCH3 or —NHCONH2;
• X is Glu which may optionally form amide bonds with its alpha carboxylic acid group, delta carboxylic acid group or amino group;
• L is a linker selected from —NH(CH2)nNH—, —NH(CH2)nCH(NH2)CO—, —OOC(CH2)mCOO—, —NH(CH2)nCO—, —NH(CH2CH2O)nNH—, —NH(CH2CH2O)nCO— or —CO(CH2CH2O)nCO—;
• R1 is free C-terminal, amidated C-terminal or N-terminal of Am1;
• or is (C1-C20)acyl substitution;
• R2 is free C-terminal, amidated C-terminal or N-terminal of Am2;
• or Y—R5;
• Y is an optional linker selected from —OOC(CH2)mCOO—, —CO(CH2)nNH—, —CO(CH2CH2O)nNH— or —COCH2(OCH2CH2)nNH—;
• R5 is an albumin binding moiety such as maleimido propionic acid;
• R3 is free alpha C-terminal, amidated alpha C-terminal or N-terminal of Glu;
• ‘n’ is an integer selected from 2 to 10, both inclusive;
• ‘m’ is an integer selected from 0 to 8, both inclusive;
• wherein one or more or all amino acids may be in a D-configuration;
• or its retro analogue or a pharmaceutically acceptable stereoisomer or a pharmaceutically acceptable salt thereof.